Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D D Christ

Showing results (21-30 of 26) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 26 results.
The Journal of Pharmacology and Experimental Therapeutics|March 1, 1994
The pharmacokinetics and pharmacodynamics of the angiotensin II receptor antagonist losartan potassium (DuP 753/MK 954) in the dogD D Christ, P C Wong, Y N Wong, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|October 26, 1999
Identification and characterization of efavirenz metabolites by liquid chromatography/mass spectrometry and high field NMR: species differences in the metabolism of efavirenzA E Mutlib, H Chen, G A Nemeth, et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|December 13, 2006
Glucuronidation in the chimpanzee (Pan troglodytes): studies with acetaminophen, oestradiol and morphineH Wong, J E Grace, M R Wright, et al.
Clinical Pharmacology and Therapeutics|January 1, 1997
DuP 532, an angiotensin II receptor antagonist: first administration and comparison with losartanM R Goldberg, M W Lo, D D Christ, et al.
Toxicology and Applied Pharmacology|November 15, 2000
The species-dependent metabolism of efavirenz produces a nephrotoxic glutathione conjugate in ratsA E Mutlib, R J Gerson, P C Meunier, et al.
Journal of Medicinal Chemistry|July 27, 2001
Design, synthesis, and structure-activity relationships of macrocyclic hydroxamic acids that inhibit tumor necrosis factor alpha release in vitro and in vivoC B Xue, M E Voss, D J Nelson, et al.
Pageof 3

Showing results (21-30 of 26) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 26 results.
The Journal of Pharmacology and Experimental Therapeutics|March 1, 1994
The pharmacokinetics and pharmacodynamics of the angiotensin II receptor antagonist losartan potassium (DuP 753/MK 954) in the dogD D Christ, P C Wong, Y N Wong, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|October 26, 1999
Identification and characterization of efavirenz metabolites by liquid chromatography/mass spectrometry and high field NMR: species differences in the metabolism of efavirenzA E Mutlib, H Chen, G A Nemeth, et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|December 13, 2006
Glucuronidation in the chimpanzee (Pan troglodytes): studies with acetaminophen, oestradiol and morphineH Wong, J E Grace, M R Wright, et al.
Clinical Pharmacology and Therapeutics|January 1, 1997
DuP 532, an angiotensin II receptor antagonist: first administration and comparison with losartanM R Goldberg, M W Lo, D D Christ, et al.
Toxicology and Applied Pharmacology|November 15, 2000
The species-dependent metabolism of efavirenz produces a nephrotoxic glutathione conjugate in ratsA E Mutlib, R J Gerson, P C Meunier, et al.
Journal of Medicinal Chemistry|July 27, 2001
Design, synthesis, and structure-activity relationships of macrocyclic hydroxamic acids that inhibit tumor necrosis factor alpha release in vitro and in vivoC B Xue, M E Voss, D J Nelson, et al.
Pageof 3